Immunservice GmbH
Booth number: 180-14
immunservice.com/en/
About us
Well tolerated innovative immunotherapy - biologicals - we are looking for partners for final MA activities
Immunservice has particularly well tolerated innovative proprietary Interleukin-2 based therapy products in GMP quality for areas of high unmet need, particularly in the fields of 1) oncology, 2) metabolic control /weight loss, 3) virology 4) neurology 5) pain management and 6) animal health.
Overcome immune exhaustion / immune senescence
Our drug candidates have unique properties, are very well tolerated and have shown a significant potential to overcome immune exhaustion and immune senescence and offer chances to strengthen and restore immune functions, induce tumor regression, act antiviral and counteract neurologic deficiencies.
Top expertise in local, particular inhalation application
In particular local applications such as inhalation of our interleukin-2 based drug candidates have an exciting potential to control respiratory tumors. Immunservice is the expert in local immune modulation and has the largest clinical experience in patients using inhalation / respiratory application of interleukin-2 based therapies. Inhalation of interleukin-2 induces complete and partial responses and allows long-term control of tumours in the respiratory tract in diseases of high need (e.g. renal cell carcinoma, melanoma, primary lung cancer and other lung metastases targeting block buster and orphan markets). EMA Orphan Designation for inhalation use in renal cell cancer.
Entering clinical trials
Immunservice has drug candidates in GMP quality and is about to start phase I and II clinical trials of its advanced development program. Immunservice has developed unique Interleukin-2 based drug candidates particularly for specialized forms of applications such as topical, mucosal, respiratory and inhalation application, which have important advantages. It is critical to use interleukin-2 in local approaches for success and tolerability and requires specialized drug candidates with designed qualities.
Game changer potential particularly for high unmet need
Interleukin-2 based therapies also have an impressive potential beyond oncology and there is evidence that they will be game changers in virology, neurology, weight loss and other metabolic diseases and pain management. Are you interested to discuss and partner additional potentials of our drug candidates, such as weight loss and metabolic control, antiviral activities, use in neurologic diseases such as amyotrophic lateral sclerosis, Parkinson Disease, or animal health and more, we are open and happy to discuss this further. Immunservice is looking for partners to make these urgently needed treatments available to human and animal patients and we are looking for you to co-operate within our clinical developments, particularly the promising respiratory / inhalation application. You are interested in animal health? Limited market classification is granted and the potential benefit of the availability of the product on the market has been confirmed by EMA. Talk to us, animal health is a very attractive area, too.
Address
Christoph Probst Weg 4
20251 Hamburg
Germany
E-mail: huland@immunservice.com
Phone: +49 40 61135184
Internet: immunservice.com/en/
Contact person:
Prof. Dr. Dr. Edith Huland
CEO / Managing Director
E-mail: huland@immunservice.com
Phone: +49 40 61135184
Products & Services
Here you find two product categories as examples, we cover a lot more. Feel free to contact us, when you are interested for co-development / partnership and look for products in 1) oncology, 2) metabolic control /weight loss, 3) virology 4) neurology 5) pain management and 6) animal health. We are happy to tailor our exciting immunotherapy products to your expectations. They are well tolerated and ready for patients in high need. We look for partners interested in real win-win situations. We look forward to talk to you!
Animal Health Biological for dogs, cats, horses and more.... Limited Market (EMA) available.
A Biological for Animal Health : against viral infection and against tumors for dogs, cats, horses and more..... Field study indicate antiviral activity and tumor responses and activity against immune exhaustion and immune senescence. EMA classification for limited markets and potential benefit of the availability of the product on the market. You find papillomavirus induced tumors on the horse Lanthanos before and at 6 months after treatment start, showing a complete response of this huge virus infected area.
